65,437 trials
Seasonal Allergic Rhinitis
Primary: Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15 — -3.29; -3.36; -2.97; -2.44 units on a scale — p=0.002
HIV Infections
Primary: Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF)) — -1.43; -1.55; -1.47 Log10 copies/mL — p=0.997
Smallpox
Primary: Number of Participants Reporting Moderate or Greater Solicited Local Reactions — 3; 0; 1; 6 Participants
Hypercholesterolemia
Primary: Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6 — -30.8; -10.9 Percent — p=<0.001
Healthy
Primary: Maximum Serum Concentration (Cmax) — 12.0435; 4.6907; 4432.4089; 12.5585 ng/ml
Carcinoma, Renal Cell Metastasis
Primary: Objective Response (Complete Response[CR] + Partial Response[PR]) in Subjects — 15; 6 participants
Autistic Disorder · Attention Deficit Disorder With Hyperactivity
Primary: ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score — 40.7; 38.6; 32.3; 37.3 units on a scale — p=<0.001
Hepatitis C, Chronic
Primary: Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment…
Hepatitis B
Primary: Number of Participants With Immunological Response to Challenge Dose in Terms of Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration — 53; 21 participants
Mild Cognitive Impairment
Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 2; 2; 3 Participants
Lymphoma
Primary: CD34+ Cells/kg in Blood Stem Cells — 7.5; 10.34 CD34+ cells/kg
Breast Cancer
Primary: Number of Lesions That Were Successfully Biopsied Using the PET-guided Biopsy Method. — 24 Number of lesions
Chronic Hepatitis B
Primary: Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48 — 75.5; 69.2 percentage of participants — p=.544
Osteoarthritis, Knee
Primary: Change in Average Pain Intensities Measured From the Pre-Treatment Walk (Baseline) at 3 Post-Treatment Walks — 0.24; 0.18; 0.18 Units on a Scale — p=0.743
Arthritis, Psoriatic
Primary: Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16 — 44; 32 participants — p=0.0210